(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 190.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12%.
Taysha Gene Therapies's revenue in 2026 is $5,485,000.On average, 14 Wall Street analysts forecast TSHA's revenue for 2026 to be $689,260,250, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $5,135,217,098. On average, 12 Wall Street analysts forecast TSHA's revenue for 2027 to be $8,985,162,716, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $33,517,480,484.
In 2028, TSHA is forecast to generate $50,915,269,965 in revenue, with the lowest revenue forecast at $29,843,599,452 and the highest revenue forecast at $97,236,558,412.